BioCryst Pharmaceuticals, Inc. (BCRX) Cash Flow Statement
BioCryst Pharmaceuticals, Inc. (BCRX) generated $376.1M of operating cash flow over the twelve months to 2026-06-30, spent $2.8M on capital expenditure and had free cash flow of $373.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
BCRXBioCryst Pharmaceuticals, Inc.Follow BCRX — free
—
Price chart with a free account
- Market cap
- 2.0B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
| Line | FY2011 Dec 11 | FY2012 Dec 12 | FY2013 Dec 13 | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.3 | -37.4 | -26.5 | -38.6 | -13.1 | -53.4 | -41.1 | -92.6 | -89.6 | -135.1 | -142.2 | -161.9 | -95.1 | -52.0 | 347.4 | 376.1 | |
| Capital expenditure | 0.1 | 0.1 | 0.0 | 0.1 | 5.1 | 5.3 | 0.3 | 0.4 | 0.3 | 0.5 | 2.4 | 1.4 | 2.2 | 1.1 | 2.5 | -2.8 | |
| Free cash flow | -32.3 | -37.5 | -26.6 | -38.7 | -18.2 | -58.7 | -41.5 | -92.9 | -89.9 | -135.6 | -144.5 | -163.2 | -97.3 | -53.1 | 344.9 | 373.4 | |
| Share repurchases | 0.1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Stock-based compensation | 4.8 | 4.2 | 4.4 | 10.2 | 9.7 | 8.5 | 12.6 | 9.4 | 17.7 | 14.8 | 34.6 | 44.7 | 55.6 | 65.4 | 85.1 | — |
USD millions · SEC XBRL
BioCryst Pharmaceuticals, Inc. — questions
- What is BioCryst Pharmaceuticals, Inc.'s operating cash flow?
- $376.1M over the twelve months to 2026-06-30.
- How much does BioCryst Pharmaceuticals, Inc. spend on capital expenditure?
- $2.8M over the twelve months to 2026-06-30.
- What is BioCryst Pharmaceuticals, Inc.'s free cash flow?
- $373.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from BioCryst Pharmaceuticals, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.